Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Kromek Group plc ( (GB:KMK) ) has provided an update.
Kromek Group plc has announced interim results marked by significant multi-year agreements with Siemens Healthineers. These agreements involve the production and supply of CZT detectors for medical imaging applications, expected to substantially boost the company’s revenue and profitability from this financial year. The initial $25 million from Siemens will support operational milestones, reduce debt, and strengthen Kromek’s balance sheet, positioning the company for sustainable growth. Despite a decrease in revenue for the first half of 2025, Kromek’s strategic initiatives, including ongoing contracts in the CBRN detection segment and advancements in biological-threat detection, indicate a robust future outlook.
More about Kromek Group plc
Kromek Group plc is a leading developer of radiation and bio-detection technology solutions, operating in the advanced imaging and chemical, biological, radiological, and nuclear (CBRN) detection segments. The company, headquartered in County Durham, UK, provides key components for medical, security, and industrial markets, focusing on enhancing disease detection and public safety. It is renowned for its cadmium zinc telluride (CZT) platform, which serves significant applications such as disease and contamination detection in medical and industrial sectors, respectively.
YTD Price Performance: 6.00%
Average Trading Volume: 1,206,073
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £34M
Learn more about KMK stock on TipRanks’ Stock Analysis page.
